by Raynovich Rod | Sep 18, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 A bit of a sell-off on end of week option expirations and cancellation of China visit to farm Bureau in MT. NAZ down 0.8%, S&P down 0.5%. Less reaction to China news now? Can biotech rally as contrian play to tech and industrials? tape in biotech was...
by Raynovich Rod | Aug 19, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update -3 Bearish trends in biopharma continue with both the IBB and XBI down with 30 min of trading to go. We will do a review of the healthcare sector later this week continuing the theme after the AACC of the need for diversification within healthcare e.g. medtech,...
by Raynovich Rod | Aug 12, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update-3…8/16 Big reversal day…summary this weekend with XBI up 2.65% at $82.46 just above support. Update-2… 8/14 Nowhere to hide from Global economic fears-welcome to whipsaw trading. Technicals matter not tweets. Market averages down about 3%...
by Raynovich Rod | Aug 6, 2019 | Clinical Diagnostics and Tools
8/10/19…XBI up 1.8% to $84.04 for 5 days, QQQ up 1.9% to $185.81 over 5 days.A good week for life science stocks with following stocks near 52 week highs: BDX BIO DHR GH HOLX NVTA 8/8/19 9:45a EDT Life Science Movers…Stocks to Watch…XBI up 0.61% to...
by Raynovich Rod | Apr 21, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 XLV up from bottom at $86 to $88.63. IBB holding but more choppy at $107 level. Update-2 12p EDT-IBB flattish at $106 as earnings on large caps come in-will be reviewed at end of week. ABBV down 0.8% on Humira concerns:, profit forecast raised EPS gains...
by Raynovich Rod | Apr 15, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 10:45a 4/17…XBI down 3.37% to FEB support at $86. Healthcare issues are spilling over to biotech.Red screen day and all biotechs hit very hard.Drug pricing models are under scrutiny. Update-1…NASDAQ ekes out small gains but large cap biotechs...
by Raynovich Rod | Mar 29, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-4. 4/3 11:45A… Mid and Small Cap biotechs are momentum leaders: XBI hits 2019 high at $92.50. Update-3 4/2/19… Biotechs Outperform Major Market Indices Gene therapy stocks rally big: SGMO 28.96%, VYGR 7.38%, CRSP 6.91% NTLA 4.9% MGTX up 4.6%,...
by Raynovich Rod | Mar 26, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3…3/29 1:15p EDT. Biotech stocks catching bids today after a choppy week of trading. We will recap our top small cap picks from the JPM Conference after the close: AMRN, GNMK and TDOC. BIIB up again to 237. CELG up over 7% as prospects for BMY deal look...
by Raynovich Rod | Feb 25, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update: 1:40 EST 2/25… Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%. Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%. ========== M&A Drives Mid and Small Cap Biotechs...
by Raynovich Rod | Feb 14, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update: GenMark (GNMK) Soars on Q4 and Full Year 2018 Results Revenues of $70.8M were 35% over 2017 Results Q4 Revenues were $19.4M an increase of 21% over prior year. ePlex Revenues for Q4 were 412.1M an increase of 110% over prior year. Loss per share was reduced...